Key Pediatric Clinical Practice Guidelines in 2017

John Anello; Brian Feinberg; John Heinegg; Yonah Korngold; Richard Lindsey; Cristina Wojdylo; Olivia Wong, DO

Disclosures

January 10, 2018

In This Article

Antiemetics in Children

American Society of Clinical Oncology

Pediatric patients who are treated with high-emetic-risk antineoplastic agents should be offered a 3-drug combination of a 5-HT3 receptor antagonist, dexamethasone, and aprepitant.

Pediatric patients who are treated with high-emetic-risk antineoplastic agents who are unable to receive aprepitant should be offered a 2-drug combination of a 5-HT3 receptor antagonist and dexamethasone.

Pediatric patients who are treated with high-emetic-risk antineoplastic agents who are unable to receive dexamethasone should be offered a 2-drug combination of palonosetron and aprepitant.

References

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....